AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05116189 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bevacizumab
Description: IV infusion
Study NCT05116189 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for pembrolizumab
Description: IV infusion
Study NCT05116189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: IV infusion
Study NCT05116189 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel
Description: IV infusion
Study NCT05494359 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: The nitrogen isotope
Description: The nitrogen isotope of various mass in oral gas were detected.
Study NCT05521399 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI Sequencing
Description: MRI test-retest (select healthy volunteers) for development of MRI sequence.
Study NCT05521399 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI Testing (pediatric)
Description: Comprehensive cardiac MRI measures will be evaluated for the identification of complications after heart transplantation (ACR, CAV) in children.
Study NCT05521399 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI Testing
Description: Cardiac MRI to improve HTx monitoring for ACR and CAV as well as outcome prediction
Study NCT05691439 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep extension and advance
Description: Participants in the sleep extension and advance condition will maintain a stable sleep schedule that extends sleep duration and advances bedtime by 90 min relative to weekday bedtime. This chronotherapeutic manipulation will include blocking phase-delaying light in the evening using goggles with orange lenses (blue blockers) beginning 2 h prior to bedtime, and 30 min of 506 lux blue-green light exposure in the morning beginning at rise time using bright light goggles (ReTimer Pty Ltd., Australia). Schedule and chronotherapy adherence will be reinforced using motivational techniques (e.g., securing motivation, preplanning, problem-solving), requiring participants to text the study coordinator and complete morning assessments at rise time, and monetary incentives.
Study NCT05691439 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regular sleep duration and timing
Description: Participants in the regular sleep duration and timing condition will keep a stable sleep schedule that matches their typical weekday sleep opportunity and timing. Schedule adherence will be reinforced using motivational techniques (e.g., securing motivation, preplanning, problem-solving), requiring participants to text the study coordinator and complete morning assessments at rise time, and monetary incentives.
Study NCT06514248 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: V5med Lung AI
Description: During the second reading session (concurrent read), the radiologist will be presented with a standard appearing CT with CADe marks placed on the left window and the same original without any AI mark with be display on the right window. Deeming a nodule, the radiologist will mark location. These may or may not correspond to the locations of the CADe markers. As in the baseline study, the radiologist will assign a level of suspicious to each mark and provide a Lung-RADS score and the size of longest dimension.
Study NCT05792930 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive-behavioral therapy and biofeedback therapy
Description: Complete eight sessions of cognitive-behavioral therapy and biofeedback therapy within three months.
Study NCT05327543 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Iyengar Yoga
Description: Iyengar Yoga focuses on the correct alignment of the body while practicing the physical exercises of yoga. Props are used to support the body in finding the right alignment. Relaxation is also part of this intervention. Participiants receive 1x90 min guided yoga class per week for 8 weeks and are encouraged to continue their practice at home daily for at least 30 minutes.
Study NCT05327543 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditative Yoga
Description: Meditative Yoga in the context of this study means practicing the physical exercises of yoga as well as meditation. Additionally, each week one of the yamas/niyamas, which are ethical principles to live by in the Yoga philosophy, will be presented at the beginning of each class and will form the theme of the class. Participants receive 1x90 min guided yoga class per week for 8 weeks and are encouraged to continue their practice at home daily for at least 30 minutes.
Study NCT06631092 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oral DNA Vaccine
Description: Bacteria-based orally administered personalised neoantigen-targeting cancer vaccine
Study NCT05649553 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: digital game and video animation based diabetes education
Description: While creating the digital game and video animation, an agreement was made with a software company and this company was responsible for the software and repair of the game. Digital games and video animations cover the basic educational topics of Type 1 diabetes. Expert opinions were received from experts in the field of Child Health and Disease Nursing to ensure the suitability of the content of the educational material. The name of the game site and how to use it were explained to the children in the intervention group by the researcher. In addition, children in the intervention group were given usernames and passwords to log in to the site. Game Sections; What is Diabetes? Medical Nutrition Treatment in Diabetes, Insulin Treatment and Application, Exercise and Physical Activity in Diabetes, Complications of Type 1 Diabetes Mellitus, Diabetes Management at School.
Study NCT04725903 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High-Dose Rate Brachytherapy
Description: Receive high-dose rate brachytherapy boost
Study NCT04725903 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Radiation Therapy
Description: Undergo proton beam therapy
Study NCT05582122 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV16 Ct-DNA dosing
Description: Droplet based digital PCR (ddPCR) technology is a novel method for performing digital PCR. A sample is fractionated into 20,000 droplets, PCR amplification of the template molecules occurs in each individual droplet.~ddPCR allows to generate quantitative and accurate data without standard curves and also present higher sensitivity compared to conventional quantitative PCR (qPCR). Indeed, this method is based on the realization of millions of single-molecule PCRs in parallel in independent compartment (here droplets of an emulsion) and consequently avoids the bias seen in conventional PCR.~ddPCR offers an optimized approach for the sensitive detection and quantification of low-target-abundance biological samples.~DNA extraction will be planned on 1 mL of plasma, which will further increase the sensitivity of our technique initially based on only 200µL of DNA extracted plasma.
Study NCT05572554 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot Bath Group
Description: The elderly were asked to soak their feet in the water in a marked plastic container with a depth of 10 centimeters and a temperature of 41-42°C for 20 minutes up to their ankles 50 minutes before normal sleeping hours every night for 8 weeks.
Study NCT05262231 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Breastfeeding Education
Description: Breastfeeding education will be announced with a poster on social media. At the same time, mothers will be informed about the training in the institution where the institution permission is obtained. Postpartum period 4-8. A single-blind randomization method will be used per week. Pre-test will be applied to the mothers in the experimental and control groups. After the pre-test, online breastfeeding training will be given to the experimental group. The training consists of a single session. It will take about 40-60 minutes. The content of the training includes the benefits of breastfeeding for the mother, baby and society, breast problems and solutions, causes and solutions of breast rejection, breastfeeding positions, etc. consists of topics. After the training experimental group, the post-test will be applied. At the same time, the post-test will be applied to the control group who did not receive the training.
Study NCT06663631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chlorpromazine and promethazine
Description: C+P were diluted to 50 ml saline solution and delivered intravenously at the beginning of endovascular thrombectomyat a velocity of 4ml/h. The whole period of drug delivery lasts for approximately 12h.
Study NCT06663631 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: 50 ml saline solution was set as placebo and delivered intravenously at the beginning of endovascular thrombectomyat a velocity of 4ml/h. The whole period of drug delivery lasts for approximately 12h.
Study NCT06663631 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: endovascular thrombectomy
Description: All patients that are eligible for endovascular thrombectomy will receive this surgery in aim to remove thrombus and restore reperfusion.
Study NCT06663631 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endovascular thrombectomy
Description: All patients that are eligible for endovascular thrombectomy will receive this surgery in aim to remove thrombus and restore reperfusion.
Study NCT06663631 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: rt-PA
Description: All patients that are eligible for Intravenous thrombolysis will receive 0.9mg/kg rt-PA in aim to remove thrombus and restore reperfusion
Study NCT06663631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rt-PA
Description: All patients that are eligible for Intravenous thrombolysis will receive 0.9mg/kg rt-PA in aim to remove thrombus and restore reperfusion
Study NCT06699056 — intervention group
Intervention type: DEVICE
Intervention: 15-minutes of sitting during COR ECG Acquistion
Description: Participants will follow a standardized protocol during a 15-minute seated session using the Peerbridge COR™ device. Participants will sit comfortably in an upright chair with a straight back; armrests are optional. Their feet must remain flat on the floor with legs uncrossed to ensure unobstructed blood flow and a stable posture. Arms should be relaxed and placed in their lap, on a flat surface (e.g., table), or on the armrest, ensuring they are not tensed or elevated. Participants will maintain a straight back with relaxed shoulders throughout the session.~To begin, participants will press the Event Button on the Peerbridge COR™ mobile device, marking the start of the session. They will remain seated in this position for 15 minutes. At the end of the session, participants will press the Event Button again to mark the conclusion of the seated event. This protocol ensures consistent data collection across all participants.
Study NCT06628089 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: A questionnaire for primary healthcare physicians designed to evaluate knowledge about H. Pylori mode of transmission, symptoms, complications and treatment.
Study NCT06627348 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hilotherm ChemoCare
Description: Hilotherapy
Study NCT05191238 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IUD self-removal education
Description: Two part educational intervention (watching IUD self-removal video and practicing IUD removal on two simulation models)
Study NCT05939011 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Well-formulated Ketogenic Diet
Description: 1:1 ketogenic diet that is focused on intake of high-quality fats (nuts/seeds, fatty fish, avocado) and reduction in processed food.
Study NCT04232306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: Bupivacaine liposome injectable suspension
Study NCT04232306 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl
Description: Bupivacaine HCl surgical-site incision infiltration
Study NCT04232306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine HCl
Description: Bupivacaine HCl surgical-site incision infiltration
Study NCT05435040 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: proprioceptive knee brace
Description: the patient will perform the tests with the knee brace
Study NCT05435040 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: No knee brace
Description: the patient will perform the tests without the knee brace
Study NCT04581447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin will start at dose of 850 mg once daily and, at one month increased to 850 mg twice daily
Study NCT04581447 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: Standard Care
Study NCT04581447 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care
Description: Standard Care
Study NCT04581447 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standardized meal
Description: Measurements of metformin-induced enterohormones secretion will be done after standardized meal test in a subgroup of patients (ancillary study)
Study NCT04725903 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04725903 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT06081348 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: Oral capsule (25mg, 50mg, 100mg, 200mg)
Study NCT06081348 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo capsule
Study NCT06461013 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Blood flow restriction
Description: A common clinical tourniquet (7cm \* 50cm in size) is placed in the middle section of the patient's thigh on the affected side, connected to a pressure gauge, observed and gradually pressurized to 160-170mmHg for about 10 minutes, then depressurized for 1 minute, and then re pressurized to 160-170mmHg. Each training session lasts for 20 minutes, once a day, five times a week, for a total of 8 weeks.
Study NCT06350162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Serplulimab
Description: 4.5mg/kg,IV over 30 minutes +/- 10 minutes on day 1. Cycles repeat every 21 days.
Study NCT06350162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab
Description: 4.5mg/kg,IV over 30 minutes +/- 10 minutes on day 1. Cycles repeat every 21 days.
Study NCT06350162 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chest Radiation
Description: 30Gy-45Gy/QD/3Gy
Study NCT04895020 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 9-valent HPV vaccine
Description: 9-valent HPV recombinant vaccine (Hansenula Polymorpha) All subjects aged 9 to 45 years received 3 doses of 9v HPV vaccine at 0,2,6 month scehdule
Study NCT04776369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine IV
Description: single-bolus of lidocaine IV 4 mg/kg
Study NCT04859049 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: infromedial single injection
Description: Group 1: We used a 25G/ 1 length needle to inject 3ml of lidocaine: bupivacaine (1:1) with 30 IU hyaluronic acid, 0.5ml below the inferior punctum in the lower lid medial margin.
Study NCT04859049 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: medial canthus injection
Description: : We used a 25G/ 1 length needle to inject 3ml of lidocaine: bupivacaine (1:1) with 30 IU hyaluronic acid classical medial canthal injection
Study NCT04776369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate Injection
Description: single-bolus of magnesium sulfate IV 30 mg / kg
Study NCT04776369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV saline
Description: Saline IV 50 ml
Study NCT04776369 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV saline
Description: Saline IV 50 ml
Study NCT05872425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DingKunDan(GuangYuYuan)
Description: The experimental group would be given DingKunDan, the subjects should take 3.5g each time, twice a day.~Subjects in the control group only needed to take COC. Both groups take medicine for 3 months consecutively as a course of treatment.
Study NCT05872425 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DingKunDan(GuangYuYuan)
Description: The experimental group would be given DingKunDan, the subjects should take 3.5g each time, twice a day.~Subjects in the control group only needed to take COC. Both groups take medicine for 3 months consecutively as a course of treatment.
Study NCT05872425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drospirenone and Ethinylestradiol Tablets (Ⅱ)
Description: The experimental group and the control group would be given oral Drospirenone and Ethinylestradiol Tablets (Ⅱ). According to the packaging instructions, on the first day of menstruation, according to the packaging instructions, the subjects should take the tablet, then take the rest sequential at the same time every day for 28 consecutive days, menstruation would happen after drug withdrawal (or after 7 days of drug withdrawal), and the next medication cycle begin on the first day of menstruation.
Study NCT05409885 — intervention group
Intervention type: OTHER
Intervention: General anesthesia
Description: Evaluate the effects of general anesthesia on NLR, PLR and MPV in patients undergoing cesarean section.
Study NCT05409885 — intervention group
Intervention type: OTHER
Intervention: Spinal anesthesia
Description: Evaluate the effects of spinal anesthesia on NLR, PLR and MPV in patients undergoing cesarean section.
Study NCT04944979 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Kedrion IVIG 10%
Description: Kedrion intravenous immunoglobulin (IVIg) 10%
Study NCT06574269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLC590
Description: Sequentially enrolled into increasing dose cohorts from low to high to receive a dose of TLC590
Study NCT06574269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLC590
Description: TLC590 Dose 1
Study NCT05471193 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Machine Learning Prediction
Description: Machine Learning Prediction
Study NCT06423586 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Curcuma longa and Boswellia serrata extracts
Description: Participants received 500 mg of Curcuma longa and 150 mg of Boswellia serrata extracts (Meriva™ and Casperome™) twice daily for 30 days.
Study NCT06423586 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcuma longa and Boswellia serrata extracts
Description: Participants received 500 mg of Curcuma longa and 150 mg of Boswellia serrata extracts (Meriva™ and Casperome™) twice daily for 30 days.
Study NCT06574269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLC590
Description: TLC590 Dose 2
Study NCT06574269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLC590
Description: The MTD of TLC590
Study NCT06574269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLC590
Description: TLC590 Dose 3 (The SMC-suggested dose)
Study NCT06574269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Ropivacaine
Study NCT05468671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: Remimazolam is a new drug innovation in anesthesia. It combines the properties of two unique drugs already established in anesthesia - Midazolam and remifentanil. It acts on GABA receptors like midazolam and has organ-independent metabolism like remifentanil.
Study NCT05468671 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol is used to put you to sleep and keep you asleep during general anesthesia for surgery or other medical procedures.
Study NCT05468671 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: Rocuronium is a non-depolarizing neuromuscular blocker
Study NCT05468671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: Rocuronium is a non-depolarizing neuromuscular blocker
Study NCT05468671 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil is an esterase-metabolized opioid
Study NCT05468671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Remifentanil is an esterase-metabolized opioid
Study NCT05468671 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxycodone
Description: Oxycodone is an opiate painkiller.
Study NCT05468671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxycodone
Description: Oxycodone is an opiate painkiller.
Study NCT05468671 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex Sodium
Description: Sugammadex sodium is an organic sodium salt that is the octasodium salt of sugammadex. Used for reversal of neuromuscular blockade induced by rocuronium and vecuronium in adults undergoing surgery
Study NCT05468671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex Sodium
Description: Sugammadex sodium is an organic sodium salt that is the octasodium salt of sugammadex. Used for reversal of neuromuscular blockade induced by rocuronium and vecuronium in adults undergoing surgery
Study NCT05468671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flumazenil
Description: Flumazenil is used to reverse the effects of a benzodiazepine